Trial Outcomes & Findings for Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal (NCT NCT02244554)

NCT ID: NCT02244554

Last Updated: 2023-02-21

Results Overview

Physician's Global Assessment (min=0; Max=4) Higher scores indicate better outcomes

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

12 weeks

Results posted on

2023-02-21

Participant Flow

Unit of analysis: Sides of tattoos treated

Participant milestones

Participant milestones
Measure
All Study Participants
Subject tattoos were divided into 2 sides for assignment into 2 arms for treatment by the Picosecond and Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) : active control arm and treatment arm. One side will receive treatment with the picosecond pulse duration and one side will receive treatment with the nanosecond pulse duration.
Overall Study
STARTED
10 20
Overall Study
Treatment With Picosecond Pulse Duration
10 10
Overall Study
Treatment With Nanosecond Pulse Duration
10 10
Overall Study
COMPLETED
10 20
Overall Study
NOT COMPLETED
0 0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Enrolled Subjects All Enrolled Subjects
n=10 Participants
Picosecond and Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Sex: Female, Male
Female
8 Participants
n=99 Participants
Sex: Female, Male
Male
2 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 12 weeks

Physician's Global Assessment (min=0; Max=4) Higher scores indicate better outcomes

Outcome measures

Outcome measures
Measure
enLighten Laser Picosecond Pulse
n=10 Participants
Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment enLighten Laser: Picosecond pulse-duration pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
enLighten Laser Nanosecond Pulse
n=10 Participants
Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment enLighten Laser: Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
Level of Tattoo Clearing at 12 Weeks for Each Treatment Arm as Assessed by the Blinded Reviewers.
3 score on a scale
Standard Deviation .94
3 score on a scale
Standard Deviation .82

Adverse Events

enLighten Laser Picosecond Pulse

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

enLighten Laser Nanosecond Pulse

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
enLighten Laser Picosecond Pulse
n=10 participants at risk
Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment enLighten Laser: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
enLighten Laser Nanosecond Pulse
n=10 participants at risk
Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment enLighten Laser: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
Skin and subcutaneous tissue disorders
Erythema
100.0%
10/10 • Number of events 10 • 12 weeks
100.0%
10/10 • Number of events 10 • 12 weeks
Skin and subcutaneous tissue disorders
Edema
100.0%
10/10 • 12 weeks
100.0%
10/10 • 12 weeks
Skin and subcutaneous tissue disorders
Purpura
50.0%
5/10 • 12 weeks
50.0%
5/10 • 12 weeks

Additional Information

Margot Doucette

Cutera

Phone: 415-657-5518

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place